Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

作者：Sabrina Welland, Catherine Leyh, Fabian Finkelmeier, André Jefremow, Kateryna Shmanko, Maria A. González-Carmona, Arne Kandulski, Petia Jeliazkova, Jan Best, Thorben Fründt, Angela Djanani, Maria Pangerl, A Maieron, Richard Greil, Christina Fricke, Disorn Sookthai, Rainer Günther, Andreas Schmiderer, Henning Wege, Marino Venerito, Ursula Ehmer, Martina Müller, Christian P. Strassburg, Arndt Weinmann, Jürgen Siebler, Oliver Waidmann, Christian M. Lange, Anna Saborowski, Arndt Vogel · 发表于：Liver Cancer · 年份：2022 · DOI：10.1159/000521746 · 被引用次数：46 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies、Cancer Mechanisms and Therapy

Background: Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the efficacy of lenvatinib in a multi-center cohort (ELEVATOR) from Germany and Austria. Methods: A retrospective data analysis of 205 patients treated with first-line systemic lenvatinib at 14 different sites was conducted. Overall survival, progression free survival, overall response rate and adverse event rates were assessed and analyzed. Results: Patients receiving lenvatinib in the real-world setting reached a median overall survival of 12.8 months, which was comparable to the results reported from the REFLECT study. Median overall survival (mOS) and progression free survival (mPFS) was superior in those patients who met the inclusion criteria of the REFLECT study compared to patients who failed to meet the inclusion criteria (mOS 15.6 vs 10.2 months, HR 0.55, 95% CI 0.38-0.81, p=0.002; mPFS 8.1 vs 4.8 months HR 0.65, 95% CI 0.46-0.91, p=0.0015). For patients with an impaired liver function according to the Albumin-Bilirubin (ALBI) grade, or reduced ECOG performance status ≥2, survival was significantly shorter compared to patients with sustained liver function (ALBI grade 1) and good performance status (ECOG performance status 0), respectively (HR 1.69, 95% CI 1.07-2.66, p=0.023; HR 2.25, 95% CI 1.19-4.23, p=0.012). Additionall...